Literature DB >> 24387866

Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.

Muriel Bonnet1, Jack U Flanagan2, Denise A Chan3, Amato J Giaccia3, Michael P Hay4.   

Abstract

Two novel scaffolds, 4-pyridylanilinothiazoles (PAT) and 3-pyridylphenylsulfonyl benzamides (PPB), previously identified as selective cytotoxins for von Hippel-Lindau-deficient Renal Carcinoma cells, were used as templates to prepare affinity chromatography reagents to aid the identification of the molecular targets of these two classes. Structure-activity data and computational models were used to predict possible points of attachment for linker chains. In the PAT class, Click coupling of long chain azides with 2- and 3-pyridylanilinothiazoleacetylenes gave triazole-linked pyridylanilinothiazoles which did not retain the VHL-dependent selectivity of parent analogues. For the PPB class, Sonagashira coupling of 4-iodo-(3-pyridylphenylsulfonyl)benzamide with a propargyl hexaethylene glycol carbamate gave an acetylene which was reduced to the corresponding alkyl 3-pyridylphenylsulfonylbenzamide. This reagent retained the VHL-dependent selectivity of the parent analogues and was successfully utilized as an affinity reagent.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BOC; Click chemistry; DCM; DMF; GLUT-1; HTS; PAT; PEG; PPB; RCC; Renal cell carcinoma; SAR; Sonogashira cross coupling; TBTA; TFA; THF; TMS; Von Hippel–Lindau factor; dichloromethane; dimethylformamide; high throughput screening; polyethylene glycol; pyridylanilino thiazole; pyridylphenylsulfonyl benzamides; renal cell carcinoma; structure–activity relationship; tert-butyloxycarbonyl; tetrahydrofuran; trifluoroacetic acid; trimethylsilyl; tris-(benzyltriazolyl)amine

Mesh:

Substances:

Year:  2013        PMID: 24387866      PMCID: PMC5713883          DOI: 10.1016/j.bmc.2013.12.028

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  28 in total

1.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions.

Authors:  Hartmuth C. Kolb; M. G. Finn; K. Barry Sharpless
Journal:  Angew Chem Int Ed Engl       Date:  2001-06-01       Impact factor: 15.336

2.  Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms.

Authors:  Yi Liu; Weihe Zhang; Yanyan Cao; Yan Liu; Stephen Bergmeier; Xiaozhuo Chen
Journal:  Cancer Lett       Date:  2010-08-01       Impact factor: 8.679

Review 3.  Biochemical target isolation for novices: affinity-based strategies.

Authors:  Shin-ichi Sato; Asako Murata; Takashi Shirakawa; Motonari Uesugi
Journal:  Chem Biol       Date:  2010-06-25

Review 4.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

5.  Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.

Authors:  Denise A Chan; Patrick D Sutphin; Phuong Nguyen; Sandra Turcotte; Edwin W Lai; Alice Banh; Gloria E Reynolds; Jen-Tsan Chi; Jason Wu; David E Solow-Cordero; Muriel Bonnet; Jack U Flanagan; Donna M Bouley; Edward E Graves; William A Denny; Michael P Hay; Amato J Giaccia
Journal:  Sci Transl Med       Date:  2011-08-03       Impact factor: 17.956

6.  Rho-kinase inhibitors: pharmacomodulations on the lead compound Y-32885.

Authors:  Cédric Logé; Valérie Wallez; Elizabeth Scalbert; Christelle Cario-Tourmaniantz; Gervaise Loirand; Pierre Pacaud; Daniel Lesieur
Journal:  J Enzyme Inhib Med Chem       Date:  2002-12       Impact factor: 5.051

7.  A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.

Authors:  Yi Liu; Yanyan Cao; Weihe Zhang; Stephen Bergmeier; Yanrong Qian; Huzoor Akbar; Robert Colvin; Juan Ding; Lingying Tong; Shiyong Wu; Jennifer Hines; Xiaozhuo Chen
Journal:  Mol Cancer Ther       Date:  2012-06-11       Impact factor: 6.261

Review 8.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

Review 9.  Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics.

Authors:  Denise A Chan; Amato J Giaccia
Journal:  Cell Cycle       Date:  2008-10-12       Impact factor: 4.534

Review 10.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

View more
  3 in total

1.  Anticancer agents interacting with membrane glucose transporters.

Authors:  C Granchi; S Fortunato; F Minutolo
Journal:  Medchemcomm       Date:  2016-07-08       Impact factor: 3.597

2.  A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells.

Authors:  Lucien N Lameijer; Daniël Ernst; Samantha L Hopkins; Michael S Meijer; Sven H C Askes; Sylvia E Le Dévédec; Sylvestre Bonnet
Journal:  Angew Chem Int Ed Engl       Date:  2017-08-09       Impact factor: 15.336

3.  Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells.

Authors:  Kalpana Tilekar; Neha Upadhyay; Markus Schweipert; Jessica D Hess; Lucasantiago Henze Macias; Piotr Mrowka; Franz-Josef Meyer-Almes; Renato J Aguilera; Cristina V Iancu; Jun-Yong Choe; C S Ramaa
Journal:  Eur J Pharm Sci       Date:  2020-08-12       Impact factor: 5.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.